Costs of drug therapy in patients with ankylosing spondylitis in Brazil
| dc.creator | Marina Amaral de Ávila Machado | |
| dc.creator | Felipe Ferré | |
| dc.creator | Cristiano Soares de Moura | |
| dc.creator | Alessandra Maciel Almeida | |
| dc.creator | Eli Iola Gurgel Andrade | |
| dc.creator | Mariangela Leal Cherchiglia | |
| dc.creator | Francisco de Assis Acurcio | |
| dc.date.accessioned | 2023-10-02T15:39:34Z | |
| dc.date.accessioned | 2025-09-09T01:23:09Z | |
| dc.date.available | 2023-10-02T15:39:34Z | |
| dc.date.issued | 2016-12 | |
| dc.description.abstract | Introdução: O Sistema Único de Saúde brasileiro oferece tratamento medicamentoso gratuito para espondilite anquilosante (EA) a todos os cidadãos brasileiros. Relatamos aqui o primeiro estudo de coorte de base populacional em pacientes com EA no Brasil. O objetivo deste estudo foi avaliar os custos dos bloqueadores do fator de necrose tumoral (anti-TNF) e dos medicamentos antirreumáticos modificadores da doença (DMARDs) utilizados no tratamento de pacientes com EA no Brasil entre março de 2010 e setembro de 2013. Métodos: Foi realizado um estudo de coorte retrospectivo utilizando bases de dados administrativas. Todos os pacientes com diagnóstico de EA com idade igual ou superior a 18 anos e que receberam anti-TNF ou DMARD foram incluídos na análise. A análise de custos foi realizada sob a perspectiva do sistema de saúde e os resultados foram descritos como custo mediano mensal per capita e custo anual durante o período do estudo. Resultados: Uma busca nas bases de dados identificou 1.251 pacientes com EA que foram tratados durante o período do estudo, dos quais 63,3% eram do sexo masculino; a idade média era de 41 anos. No período do estudo, 78,0% dos pacientes iniciaram tratamento com anti-TNF e 22,0% com DMARD. O custo médio mensal per capita foi de US$ 1.650 para terapia anti-TNF e US$ 25 para tratamento com DMARDs. Entre os medicamentos anti-TNF, a terapia com etanercepte foi associada ao menor custo por paciente, seguida de adalimumabe e infliximabe. Não foi observada diferença no custo mensal em relação ao sexo e idade. Conclusão: O custo por paciente do tratamento de EA nesta coorte de estudo foi menor com etanercepte do que com adalimumabe e infliximabe. Estes resultados destacam o fardo económico do tratamento de pacientes com EA. | |
| dc.description.sponsorship | CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico | |
| dc.description.sponsorship | FAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais | |
| dc.description.sponsorship | CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior | |
| dc.format.mimetype | ||
| dc.identifier.doi | https://doi.org/10.1007/s40744-016-0036-0 | |
| dc.identifier.issn | 2198-6584 | |
| dc.identifier.uri | https://hdl.handle.net/1843/59050 | |
| dc.language | eng | |
| dc.publisher | Universidade Federal de Minas Gerais | |
| dc.relation.ispartof | Rheumatology and Therapy | |
| dc.rights | Acesso Aberto | |
| dc.subject | Espondilite anquilosante | |
| dc.subject | Inibidores do fator de necrose tumoral | |
| dc.subject | Antirreumáticos | |
| dc.subject | Custos de medicamentos | |
| dc.subject.other | Administrative claims data | |
| dc.subject.other | Ankylosing spondylitis | |
| dc.subject.other | Anti-TNF therapy | |
| dc.subject.other | DMARDs | |
| dc.subject.other | Drug cost | |
| dc.title | Costs of drug therapy in patients with ankylosing spondylitis in Brazil | |
| dc.type | Artigo de periódico | |
| local.citation.epage | 361 | |
| local.citation.issue | 2 | |
| local.citation.spage | 353 | |
| local.citation.volume | 3 | |
| local.description.resumo | Introduction: The Brazilian Public Health System offers free-of-charge drug treatment for ankylosing spondylitis (AS) to all Brazilian citizens. We report here the first population-based cohort study on patients with AS in Brazil. The aim of this study was to evaluate the costs of the tumour necrosis factor (anti-TNF) blockers and disease-modifying antirheumatic drugs (DMARDs) that were used in the treatments of patients with AS in Brazil between March 2010 and September 2013. Methods: A retrospective cohort study was performed using administrative databases. All patients with a diagnosis of AS who were aged 18 years or older and had been dispensed anti-TNF or DMARDs were included in the analysis. The cost analysis was carried out from the health system perspective, and the results were described as median monthly cost per capita and the annual cost over the study period. Results: A search of the databases identified 1251 patients with AS who were treated during the study period, of whom 63.3% were male; the median age was 41 years. During the study period, 78.0% of patients initiated treatment with anti-TNF drugs and 22.0% with DMARDs. The median monthly cost per capita was US$ 1650 for anti-TNF therapy and US$ 25 for treatment with DMARDs. Among the anti-TNF drugs, therapy with etanercept was associated with the lowest cost per patient, followed by adalimumab and infliximab. No difference in monthly cost was observed in relation to gender and age. Conclusion: The cost per patient of treating AS in this study cohort was lower with etanercept than with adalimumab and infliximab. These results highlights the economic burden of treating patients with AS. | |
| local.publisher.country | Brasil | |
| local.publisher.department | FAR - DEPARTAMENTO DE FARMÁCIA SOCIAL | |
| local.publisher.department | MED - DEPARTAMENTO DE MEDICINA PREVENTIVA SOCIAL | |
| local.publisher.initials | UFMG | |
| local.url.externa | https://link.springer.com/article/10.1007/s40744-016-0036-0 |